Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania

Simple item page
dc.contributor.authorShayo, Alex
dc.contributor.authorBuza, Joram
dc.contributor.authorIshengoma, Deus S.
dc.date.accessioned2020-03-23T08:32:28Z
dc.date.available2020-03-23T08:32:28Z
dc.date.issued2015
dc.descriptionFull Text Article. Also available at: 10.1186/s12936-015-0649-8en_US
dc.description.abstractPrompt diagnosis and effective treatment are considered the cornerstones of malaria control and artemisinin-based combination therapy (ACT) is currently the main anti-malarial drugs used for case management. After deployment of ACT due to widespread parasite resistance to the cheap and widely used anti-malarial drugs, chloroquine and sulphadoxine/pyrimethamine, the World Health Organization recommends regular surveillance to monitor the efficacy of the new drugs. The present paper assessed the implementation of anti-malarial efficacy testing for monitoring the therapeutic efficacy of ACT for treatment of uncomplicated malaria in Tanzania before and after policy changes in 2006. A literature search was performed for published clinical trials conducted in Tanzania from 2001 to 2014. It focused on studies which assessed at least one form of ACT for treatment of uncomplicated falciparum malaria in children less than 10 years and reported efficacy and safety of the tested anti-malarials. References were imported into the Endnote library and duplicates removed. An electronic matrix was developed in Microsoft Excel followed by full text review with predetermined criteria. Studies were independently assessed and information related to ACT efficacy and safety extracted. Nine papers were selected from 125 papers screened. The efficacy of both artemether lumefantrine (AL) and artesunate-amodiaquine (AS + AQ) against uncomplicated P. falciparum infections in Tanzania was high with PCR corrected cure rates on day 28 of 91-100% and 88-93.8%, respectively. The highest day-3 parasite positivity rate was 1.4%. Adverse events ranged from mild to serious but were not directly attributed to the drugs. ACT is efficacious and safe for treatment of uncomplicated malaria in Tanzania. However, few trials were conducted in Tanzania before and after policy changes in 2006 and thus more surveillance should be urgently undertaken to detect future changes in parasite sensitivity to ACT.en_US
dc.identifier.citationShayo, A., Buza, J., & Ishengoma, D. S. (2015). Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malaria Journal, 14(1), 135.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12661/2281
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectCombination therapyen_US
dc.subjectArtemetheren_US
dc.subjectLumefantrineen_US
dc.subjectArtesunateen_US
dc.subjectAmodiaquineen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectTanzaniaen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectArtemisinin-naphthoquine combinationen_US
dc.subjectMalaria controlen_US
dc.titleMonitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzaniaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Shayo A..pdf
Size:
814.29 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles